Ukr.Biochem.J. 2013; Volume 85, Issue 5, Sep-Oct, pp. 97-104


Antitoxic and antioxidant effects of N-stearoylethanolamin in the content of nanocomposite complex with doxorubicin in organs of mice with Lewis carcinoma

E. A. Gudz1, N. M. Hula1, T. N. Goridko1, Y. M. Bashta1,
A. I. Voyeikov1, A. G. Berdyshev1, H. V. Kosiakova2,
R. R. Panchuk3, R. S. Stoika2, A. A. Ryabtseva3, O. S. Zaichenko3

1Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv;
2Institute Biology of Cell, National Academy of Sciences of Ukraine, Lviv;
3National University “Lvov Politekhnika”, Ukraine

The aim of the study was to evaluate the possibility to reduce the doxorubicin toxic effects by its immobilization with N-stearoylethanolamine (NSE) on nanocarier polyethylene glycol. The studied  parameters of the doxorubicin toxicity were: the level of creatinine in the mice blood plasma and activity of alanine aminotransferase and aspartate aminotransferase in the blood plasma of mice. The activity of catalase superoxide dismutase, glutathione peroxidase and intensity of lipid peroxidation was determined in the tissues of the heart, kidneys and liver. Doxorubicin in the content of nanocarrier alone caused an increase of serum creatinine and aspartateaminotrasferase activity in plasma of experimental animals with carcinoma. Nanocomposite which contained doxorubicin and NSE, did not cause an increase of these parameters. It has been shown that the administration of a carrier containing doxorubicin to mice with Lewis lung carcinoma caused the decrease of  catalase  activity in mice with carcinoma. The combination of NSE and doxorubicin on the carrier led to the normalization of this parameter to the level of intact animals. NSE immobilized on a carrier together with doxorubicin caused a decrease in the activity of superoxide dismutase in the kidney tissue of mice with tumor. The tumor growth caused the increase of the of superoxide dismutase in mice. The administration of a carrier which contained doxorubicin and NSE normalized superoxide dismutase in heart tissue contrary of kidney. The obtained results show the antitoxic and antioxidant effects of N-stearoylethanolamine immobilized in the nanocarrier complex together with doxorubicin.

Keywords: , , , , , ,


  1. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf. 2001 Jan;24(1):19-38. Review. PubMed, CrossRef
  2. Henninger C, Huelsenbeck J, Huelsenbeck S, Grösch S, Schad A, Lackner KJ, Kaina B, Fritz G. The lipid lowering drug lovastatin protects against doxorubicin-induced hepatotoxicity. Toxicol Appl Pharmacol. 2012 May 15;261(1):66-73. PubMed, CrossRef
  3. Wang WC, Uen YH, Chang ML, Cheah KP, Li JS, Yu WY, Lee KC, Choy CS, Hu CM. Protective effect of guggulsterone against cardiomyocyte injury induced by doxorubicin in vitro. BMC Complement Altern Med. 2012 Aug 27;12:138. PubMed, PubMedCentral, CrossRef
  4. Talevi A, Gantner ME, Ruiz ME. Applications of nanosystems to anticancer drug therapy (Part I. Nanogels, nanospheres, nanocapsules). Recent Pat Anticancer Drug Discov. 2014 Jan;9(1):83-98. Review. PubMed, CrossRef
  5.  Jabr-Milane LS, van Vlerken LE, Yadav S, Amiji MM. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev. 2008 Nov;34(7):592-602. Review. PubMed, PubMedCentral, CrossRef
  6. Nair KL, Jagadeeshan S, Nair SA, Kumar GS. Evaluation of triblock copolymeric micelles of δ- valerolactone and poly (ethylene glycol) as a competent vector for doxorubicin delivery against cancer. J Nanobiotechnology. 2011 Sep 25;9(1):42. PubMed, PubMedCentral, CrossRef
  7. Berdyshev GA, Gulaya NM, Chumak AA, Kindruk NL. The effect of N-stearoylethanolamine on free amino acid levels in plasma and liver of rats with an experimental burn. Biochemistry (Moscow) Suppl. Ser. B Biomed. Chem. 2011;5(1):44-50.  CrossRef
  8. Schmid HH, Berdyshev EV. Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides: metabolism and function. Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):363-76. Review. PubMed, CrossRef
  9. Hansen HH, Ikonomidou C, Bittigau P, Hansen SH, Hansen HS. Accumulation of the anandamide precursor and other N-acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal death. J Neurochem. 2001 Jan;76(1):39-46. PubMed, CrossRef
  10. Gula NM, Khmel TO, Klimashevsky VM, Kulik HI, Todor IM. N-stearoylethanolamine inhibits growth and metastasis of the Lewis carcinoma and modulates lipid composition of the lung during tumorogenesis in mice. Ukr Biokhim Zhurn. 2006 Jan-Feb;78(1):135-42. Ukrainian.  PubMed
  11. Goudz IA, Gula NM, Khmel TO, Goridko TM, Berdyshev AG. Antioxidative effect of the N-stearoylethanolamine in the heart tissue and blood plasma of rats under doxorubicin treatment. Ukr Biokhim Zhurn. 2011 Nov-Dec;83(6):86-91. Ukrainian.  PubMed
  12. Goudz IA, Gula NM, Khmel TO, Goridko TM, Bashta YM, Panchuk RR, Stoika RS, Ryabtseva AA, Zaichenko OS. Protective effect of N-stearoylethanolamine in suspension and in nanocomposite complex in the organs of mice with the Lewis carcinoma under doxorubicin intoxication administration. Ukr Biokhim Zhurn. 2012 Jul-Aug;84(4):61-9. Ukrainian. PubMed
  13. Irwin ME, Rivera-Del Valle N, Chandra J. Redox control of leukemia: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal. 2013 Apr 10;18(11):1349-83. Review. PubMed, PubMedCentral, CrossRef
  14. Tateishi K, Ichiyama T, Hirai K, Agatsuma T, Koyama S, Hachiya T, Morozumi N, Shiina T, Koizumi T. Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group study. Med Oncol. 2013 Mar;30(1):450. PubMed, CrossRef
  15. Riabtseva A, Mitina N, Gavryliuk D, Lesyk R, Zimenkovsky B., Nadashkevych Z, Zaichenko O.Nanoscale delivery systems for anticancer drug immobilized on a polyethyleneglycol containing polymeric carrier. Visnyk NU Lviv Polytechnic. Series Chemistry, technology of substances and their applications. Lviv, 2012;(726):377-383.
  16. Riabtseva A, Mitina N, Boyko N, Nadashkevych Z, Stoika R, Zaichenko O. Synthesis of novel pegylated carriers for nanoscale drug delivery systems. Proc. Shevchenko Sci. Soc. Chem. Biochem. 2011;28:19-27.
  17. Lowry OH, Rosenbrough NJ, J., Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265-75. PubMed
  18. Koroliuk MA, Ivanova LI, Mayorova IG, Tokarev VE. A method of determining catalase activity. Lab Delo. 1988;(1):16-9. Russian. PubMed
  19. Csóvári S, Andyal T, Strenger J. Determination of the antioxidant properties of the blood and their diagnostic significance in the elderly. Lab Delo. 1991;(10):9-13. Russian. PubMed
  20. Pereslegina IA. The activity of antioxidant enzymes in the saliva of normal children. Lab Delo. 1989;(11):20-3. Russian. PubMed
  21. Vladimirov Yu.A., Archakov A.I. Lipids peroxidation in biological membranes. Moscow: Nauka, 1972; 252 p.
  22. Tietz NA.  Encyclopedia of clinical laboratory tests. 1997:277-278.
  23. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007 Jan;87(1):315-424. Review. PubMed, PubMedCentral, CrossRef
  24. Wold LE, Aberle NS 2nd, Ren J. Doxorubicin induces cardiomyocyte dysfunction via a p38 MAP kinase-dependent oxidative stress mechanism. Cancer Detect Prev. 2005;29(3):294-9. PubMed, CrossRef

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.